Source: Annual Congress 2012 - Different ways to phenotype asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R.A. Simon, D.S. Pearlman, Y. Chon, J.H. Lin, S.L. Lin (San Diego, La Jolla, Denver, Thousand Oaks, United States Of America). Safety of long-acting β-agonist (LABA) withdrawal in patients in two clinical asthma trials. Eur Respir J 2012; 40: Suppl. 56, 161

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of as-needed corticosteroid plus fast or short-acting beta-agonists monotherapy in patients with mild asthma: a meta-analysis of randomised controlled trials. Source: Virtual Congress 2020 – Inhaled corticosteroids and bronchodilator studies in asthma Year: 2020 Should guidelines be revised for add-on therapy in asthma? A 2 year randomized pragmatic equivalence trial of leukotriene antagonists (LTRAs) and long-acting beta agonists (LABAs) with inhaled corticosteroids (ICS) in primary care Source: Annual Congress 2008 - Wider aspects of managing respiratory disease in primary care Year: 2008 LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Efficacy and safety of inhaled corticosteroid‘s (ICS) and long-acting beta-agonist‘s (LABA) combination in asthma (A) patients Source: Eur Respir J 2004; 24: Suppl. 48, 125s Year: 2004 Inhaled corticosteroid (ICS) and long-acting beta2-agonist (LABA) combination vs. high doses of ICS: efficacy and safety in patients (pts) with uncontrolled occupational asthma Source: International Congress 2017 – Techniques to treat asthma Year: 2017 Safety of formoterol in asthma clinical trials Source: Annual Congress 2012 - Asthma treatment: efficacy and safety Year: 2012 Efficacy and safety of transdermal tulobuterol (LABA) on asthma patients Source: Annual Congress 2007 - New treatments for asthma Year: 2007 Long-acting β-agonists: a review of formoterol safety data from asthma clinical trials Source: Eur Respir J 2009; 33: 21-32 Year: 2009 Once-daily QVA149 demonstrates superior outcomes in COPD patients previously treated with fixed-dose long-acting beta2-agonist/inhaled corticosteroid (LABA/ICS): The ILLUMINATE study Source: Annual Congress 2013 –Asthma and COPD management: novel clinical findings Year: 2013 Safety of as-needed formoterol in asthma patients on different maintenance long-acting ß2-agonists Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies Year: 2021 Description of a randomised controlled trial of inhaled corticosteroid/fast-onset LABA reliever therapy in mild asthma Source: Eur Respir J 2016; 47: 981-984 Year: 2016 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Role of tiotropium in reducing exacerbations in COPD patients when added to long-acting beta2-agonists (LABA) and inhaled corticosteroids (ICS): The OUTPUL study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013 Safety of budesonide/formoterol maintenance and reliever therapy in asthma trials Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma Year: 2008 Tiotropium reduces the risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials Source: Annual Congress 2008 - Pathogenesis and treatment of asthma and COPD Year: 2008 Safety of formoterol in asthma clinical trials: an update Source: Eur Respir J 2014; 43: 103-114 Year: 2004 Safety of tiotropium and olodaterol fixed-dose combination for COPD in patients on β-blockers Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 First choice in persistent asthma: inhaled corticosteroids (ICS) or ICS + long-acting beta2-agonist (LABA) combination in steroid-naïve patients? Source: Annual Congress 2004 - Further pharmacological and clinical evidence for using long-acting β-agonists with inhaled corticosteroids Year: 2004 Safety of formoterol in asthma trials Source: Eur Respir J 2007; 30: Suppl. 51, 248s Year: 2007 Efficacy of long-term formoterol therapy vs as-needed salbutamol use in patients with moderate asthma Source: Eur Respir J 2001; 18: Suppl. 33, 426s Year: 2001